Biodesix Q3 2024 GAAP EPS $(0.07), Inline, Sales $18.151M Miss $18.611M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biodesix reported Q3 2024 earnings per share of $(0.07), meeting analyst expectations, but sales of $18.151 million missed the $18.611 million estimate. Despite the miss, sales increased by 34.54% compared to the same period last year.
November 01, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biodesix's Q3 2024 earnings per share met expectations, but sales fell short of estimates. However, sales showed significant year-over-year growth.
The earnings per share met expectations, which is neutral for the stock. The sales miss might be seen negatively, but the significant year-over-year growth could offset this. Overall, the impact is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100